Return on investment
Posted December 16th, 2015
Expensive pneumococcal vaccine pointing to substantial cost savings.
Public agencies and private payers are concerned about the rising costs of vaccinations. While new versions of vaccines may be more effective in preventing disease, their adoption may lead to increases in premiums and a strain on public health budgets.
Pneumococcal vaccines can prevent cases of meningitis, bacteremia, pneumonia and ear infections. In 2010, a pneumococcal vaccine that provided enhanced protection was recommended and implemented. While this new version of the vaccine was more expensive, a new analysis shows that its use may have saved both private and public payers substantially more than it cost.
How much costs savings did the new vaccine provide? Read the full text article on the Health Affairs website.